Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (Revlimid®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In Subjects With Newly Diagnosed Multiple Myeloma Who Are 65 Years Of Age Or Older
Brief Summary: The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.


Options:
A: Arm Label: Arm A: VMPT; Type: EXPERIMENTAL; Interventions: Drug: Bortezomib, Melphalan, Prednisone, Thalidomide | Arm Label: VMP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bortezomib, Melphalan, Prednisone | Intervention Type: DRUG; Name: Bortezomib, Melphalan, Prednisone, Thalidomide; Assigned to Arm(s): Arm A: VMPT | Intervention Type: DRUG; Name: Bortezomib, Melphalan, Prednisone; Assigned to Arm(s): VMP
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Melphalan/Prednisone/Velcade | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Thalidomide/Prednisone/Velcade | Intervention Type: DRUG; Name: Melphalan/Prednisone/Velcade; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Thalidomide/Prednisone/Velcade; Assigned to Arm(s): B
C: Arm Label: MPR+R; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide: Double-blind Induction, Drug: Melphalan, Drug: Prednisone, Drug: Aspirin, Drug: Lenalidomide: Double-blind Maintenance, Drug: Lenalidomide: Open-label | Arm Label: MPR+p; Type: EXPERIMENTAL; Interventions: Drug: Lenalidomide: Double-blind Induction, Drug: Melphalan, Drug: Prednisone, Drug: Aspirin, Drug: Placebo, Drug: Lenalidomide: Open-label | Arm Label: MPp+p; Type: OTHER; Interventions: Drug: Melphalan, Drug: Prednisone, Drug: Aspirin, Drug: Placebo, Drug: Lenalidomide: Open-label | Intervention Type: DRUG; Name: Lenalidomide: Double-blind Induction; Assigned to Arm(s): MPR+R, MPR+p | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): MPR+R, MPR+p, MPp+p | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): MPR+R, MPR+p, MPp+p | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): MPR+R, MPR+p, MPp+p | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): MPR+p, MPp+p | Intervention Type: DRUG; Name: Lenalidomide: Double-blind Maintenance; Assigned to Arm(s): MPR+R | Intervention Type: DRUG; Name: Lenalidomide: Open-label; Assigned to Arm(s): MPR+R, MPR+p, MPp+p
D: Arm Label: Treatment Arm A (VMP Alone); Type: ACTIVE_COMPARATOR; Interventions: Drug: Velcade, Drug: Melphalan, Drug: Prednisone | Arm Label: Treatment Arm B (D-VMP); Type: EXPERIMENTAL; Interventions: Drug: Velcade, Drug: Melphalan, Drug: Prednisone, Drug: Daratumumab IV, Drug: Dexamethasone, Drug: Daratumumab SC | Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): Treatment Arm A (VMP Alone), Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Melphalan; Assigned to Arm(s): Treatment Arm A (VMP Alone), Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Treatment Arm A (VMP Alone), Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Daratumumab IV; Assigned to Arm(s): Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Treatment Arm B (D-VMP) | Intervention Type: DRUG; Name: Daratumumab SC; Assigned to Arm(s): Treatment Arm B (D-VMP)

Answer: C